A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Latest Information Update: 12 Oct 2025
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 15 Aug 2025 Planned End Date changed from 10 Nov 2026 to 13 Apr 2027.
- 15 Aug 2025 Planned primary completion date changed from 6 Jun 2025 to 4 Aug 2026.
- 14 Aug 2024 Planned End Date changed from 4 Jun 2026 to 10 Nov 2026.